Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs. Pioglitazone Add-on in Uncontrolled Type 2 Diabetes
NCT03125694Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin with Pioglitazone (2 arms). Primary endpoint: Change from baseline in mean glycated hemoglobin (A1C) levels at 52 weeks. Started Feb 2015; status: completed.
02
Drugs
sitagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03125694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125694.